Medline Inc. announces launch of secondary offering of Class A common stock
Rhea-AI Summary
Medline (Nasdaq: MDLN) announced a secondary offering of Class A common stock by certain selling stockholders affiliated with Blackstone, Hellman & Friedman and Abu Dhabi Investment Authority.
The underwritten public offering covers 60,000,000 shares, with a 30-day option for underwriters to buy up to 9,000,000 additional shares. Medline is not selling shares and will not receive proceeds.
Positive
- None.
Negative
- Medline is not selling shares and will receive no proceeds from the offering
News Market Reaction – MDLN
In the May 20 session, MDLN declined 3.85%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.8% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Secondary closing | Negative | -1.2% | Closing of secondary sale with full underwriter option exercise by selling holders. |
| Mar 04 | Secondary pricing | Negative | +2.7% | Pricing of large secondary offering at fixed per‑share level by sponsors. |
| Mar 03 | Secondary launch | Negative | -3.2% | Launch of sizable secondary sale by private equity and sovereign holders. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent secondary/related offering headlines have produced modest single‑day moves, with an average reaction of -0.56% and a mix of aligned and divergent responses.
In the past few months, Medline has repeatedly used secondary offerings by large private equity and institutional holders, with the company itself not receiving proceeds. Prior offering headlines on Mar 3, Mar 4 and Mar 10, 2026 involved sizable Class A share sales and underwriter options. Price reactions around these events stayed relatively moderate, suggesting the market had been digesting ongoing sponsor sell‑downs rather than company-level capital raises.
Key Terms
secondary offering financial
underwritten public offering financial
registration statement regulatory
prospectus regulatory
Securities and Exchange Commission regulatory
Class A common stock financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORTHFIELD, Ill., May 20, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) have commenced an underwritten public offering of 60,000,000 shares of Medline’s Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission (the “SEC”). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 9,000,000 shares of Medline’s Class A common stock.
Medline is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale.
Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers, and Blackstone Capital Markets is acting as co-manager for the proposed offering.
The proposed offering of these securities will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar conditional or future expressions, are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements related to Medline’s industry, business strategy, costs, and cost savings, goals and expectations, market position, future operations, margins, profitability, annual guidance, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainties, and changes in circumstances, many of which are beyond Medline’s control, that could cause actual results to differ materially.
Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.
Contacts:
Investor Relations:
Karen King
Global Head Investor Relations
Patrick Flaherty
Director, Investor Relations
(847) 247-7222
IR@medline.com
Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
media@medline.com
Source: Medline Inc.
